NEW YORK, April 5 (GenomeWeb News) - Ciphergen Biosystems said yesterday that disappointing sales will cause its revenues for the first quarter to fall significantly short of earlier expectations. The company now expects to generate between $6.3 million and $6.7 million in revenues - or about half its receipts during the same period last year.
Registering provides access to this and other free content.
Already have an account?Login Now.
In PLOS this week: genomic analysis of honeybee disease, microRNA profiles of people with lupus nephritis, and more.
The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.
Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.
In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.